Ocriplasmin

Jetrea

0.5MG/0.2ML InjectionUnited StatesWithdrawnAuthorised 17 Oct 2012

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Ocriplasmin

Jetrea

0.5MG/0.2ML InjectionUnited StatesWithdrawnAuthorised 17 Oct 2012

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Documents

The official texts, at the regulator.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Register entryFDA

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

U.S. Food and Drug Administration

FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.

Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions · Added 11 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Ocriplasmin
Strength: 0.5MG/0.2ML
Dosage form: Injection
Route: Intravitreal
Register: United States (FDA)
Status: Withdrawn
Status in the register: Voluntarily Revoked / Disc
Authorised: 17 Oct 2012
Registration: BLA 125422
Marketing authorisation holder: ThromboGenics Inc.
Procedure: 351(a)
Supply: Disc